Study: CBD has Longer Treatment Window for Newborn Brain Damage than Other Treatments

Study: CBD has Longer Treatment Window for Newborn Brain Damage than Other Treatments

A new study being published in the upcoming issue of the journal CNS & Neurological Disorders – Drug Targets, and published online by the National Institute of Health, has found that cannabidiol (CBD) can treat newborn brain damage, and can do so when administered longer after a dramatic event than other treatment options.

According to the study’s abstract, its purpose was “to test the TTW [therapeutic time window] of the neuroprotective effects of cannabidol (CBD), a non-psychoactive cannabinoid in a model of newborn HI brain damage.”

In doing so, researchers administered CBD to newborn mice with brain damage; it was administered 15 minutes after the induction of brain damage, and then 1, 3, 6, 12, 18 and 24 hours after.

Researchers found that “CBD administered up to 18 h after HI [hypoxic-ischemic brain damage] reduced IHVL and neuropathological score by 60%, TUNEL+ count by 90% and astrocyte damage by 50%. In addition, CBD blunted the HI-induced increase in microglial population.”

However, when CBD administration was delayed 24 hours, these effects were greatly reduced.

The study concludes; “CBD shows a TTW of 18 h when administered to HI newborn mice, which represents a broader TTW than reported for other neuroprotective treatments including hypothermia.”

The full study can be found on the National Institute of Health’s website by clicking here.